Prostate Cancer P D:恩杂鲁胺对前列腺癌患者的疲劳有什么影响?

2021-09-28 AlexYang MedSci原创

利用四项恩杂鲁胺-安慰剂对照试验中患者报告的结果,评估了恩扎鲁胺对患者报告的疲劳的影响。

在整个前列腺癌患病过程中,不同患者的经历存在差异,随着疾病向转移(m)去势抵抗性前列腺癌(CRPC)发展,症状也会随之恶化。前列腺癌患者报告的主要症状之一是疲劳,可能由疾病本身、治疗和高龄引起。前列腺癌患者在早期阶段,即疾病定位后并开始雄性激素剥夺治疗(ADT)时,已经存在疲劳症状。当患者接受化疗或新的激素类药物治疗,且与ADT联合治疗时,患者报告的疲劳可能会恶化。疲劳是许多前列腺癌药物的一个常见不良事件(AE ),如阿比特龙、恩扎鲁胺、阿帕鲁胺、多西他赛、达洛鲁胺、镭-223、卡巴他赛和奥拉帕尼。

近期,来自比利时的研究人员在《Prostate Cancer P D》上发表文章,利用四项恩杂鲁胺-安慰剂对照试验(ARCHES(NCT02677896)、PROSPER(NCT02003924)、PREVAIL(NCT01212991)和AFFIRM(NCT00974311))中患者报告的结果,评估了恩扎鲁胺对患者报告的疲劳的影响

在各个研究中,研究人员使用癌症治疗功能评价量表-前列腺项GP1,在基线、第13或17周,以及之后每12周对疲劳进行评估,直到疾病发生进展。研究结果发现,晚期疾病(转移性和/或去势抵抗性前列腺癌(CRPC))患者和已经接受过治疗的患者,基线时的疲劳率较高;PROSPER(非转移性CRPC)的疲劳率为58%,AFFIRM(多西他赛治疗后的转移性CRPC)的疲劳率为86%。无论疾病状态如何,开始使用恩杂鲁胺或安慰剂都会导致疲劳感增加(到第13或17周),此后疲劳感水平趋于稳定。在该研究的最后一次评估中,与基线相比,所有试验中≥55%的患者报告疲劳有所改善或稳定。在ARCHES、PROSPER和PREVAIL中,与安慰剂+ADT相比,有更多的患者报告恩杂鲁胺+雄性激素剥夺疗法(ADT)的疲劳度恶化≥1或≥2个单位,但所有的组间差异<10%。

患者疲劳恶化或者改善的比例情况

综上所述,疲劳的程度在mCRPC中更高,而在疾病的早期则较低。在开始恩杂鲁胺或安慰剂治疗后13-17周,疲劳感均增加,而恩杂鲁胺治疗更高,此后稳定或有所改善

原始出处:

Bertrand F Tombal , Stephen J Freedland , Andrew J Armstrong et al. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer P D. Sep 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791654, encodeId=60b41e91654f9, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jan 12 05:32:04 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260941, encodeId=3f8a12609415a, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364755, encodeId=c59d1364e5573, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602388, encodeId=1207160238864, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791654, encodeId=60b41e91654f9, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jan 12 05:32:04 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260941, encodeId=3f8a12609415a, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364755, encodeId=c59d1364e5573, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602388, encodeId=1207160238864, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 tamgche
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791654, encodeId=60b41e91654f9, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jan 12 05:32:04 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260941, encodeId=3f8a12609415a, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364755, encodeId=c59d1364e5573, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602388, encodeId=1207160238864, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791654, encodeId=60b41e91654f9, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jan 12 05:32:04 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260941, encodeId=3f8a12609415a, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364755, encodeId=c59d1364e5573, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602388, encodeId=1207160238864, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Sep 30 11:32:04 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 sunylz

相关资讯

JU:经会阴标准网格法与自由手方法对前列腺穿刺结果比较

通常是经直肠/会阴的活检结果作为PCa诊断的标准检查,随着技术的发展标准网格法(GB)和自由手(FH)方法在临床上应用的越来越多,但是哪种方法更适合仍然存在争议。

EU:中、高危前列腺癌根治性前列腺切除术中扩大或局限盆腔淋巴结清扫术的价值

中、高危前列腺癌根治性前列腺切除术中扩大或局限盆腔淋巴结清扫术在短期内对患者的预后没有明显差异。

JU:低风险前列腺癌患者中主动监测中断的相关因素

随着时间的推移,AS的使用率显著增加,但5年以上的中断率相对较高。

EU:双极雄激素对接受阿比特龙或恩杂鲁胺患者治疗后的应用价值

双极雄激素对接受阿比特龙或恩杂鲁胺患者治疗后的应用价值

OXID MED CELL LONGEV:不止提神又美味,这种打工人“完美饮料”还能抗癌!

综述:咖啡作为抗癌饮料的十年研究。含or不含咖啡因更好?喝多少杯合适?该注意什么?齐活!

J Urol:影响前列腺癌患者从主动监测转变为治疗的因素

调查了与男性前列腺癌患者从主动监测转为治疗时间间隔有关的人口统计学和临床病理学参数。